ArticleAnnals of nuclear medicine2026
Predictive value of metabolic parameters from PET/CT in adult multifocal Langerhans cell histiocytosis.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to explore the potential of 18F-FDG PET/CT-derived metabolic parameters in predicting the prognosis of adults with multifocal Langerhans cell histiocytosis (LCH).
methodsThis retrospective study included adult patients with pathologically confirmed multifocal LCH who underwent baseline 18F-FDG PET/CT scans at our institution and received appropriate treatment. The semi-quantitative PET/CT parameters evaluated included whole-body metabolic tumor volume (WBMTV), whole-body total lesion glycolysis (WBTLG), and maximum standardized uptake value (SUVmax). Receiver operating characteristic curve analysis was used to determine the optimal cut-off values for the metabolic parameters. Progression-free survival (PFS) analysis was performed for clinical features and PET/CT parameters using the log-rank test, Kaplan-Meier curves, and Cox proportional hazards models to identify prognostic factors for PFS.
resultsA total of 33 patients (22 male, 11 females; mean age 39 years, range 18–73 years) were included. During the follow-up period, 15 patients (45.5%) experienced disease progression or relapse. Univariate analysis revealed that age > 50 years, positive risk organs, SUVmax > 13, WBMTV > 36.79, and WBTLG > 277.22 were significantly associated with poor PFS (all p < 0.05). In multivariate analysis, SUVmax > 13 (HR = 4.521, 95% CI 1.137–17.968), WBMTV > 36.79 (HR = 13.278, 95% CI 1.415–124.569), and WBTLG > 277.22 (HR = 5.643, 95% CI 1.059–30.077) remained independent prognostic factors for PFS with statistical significance.
conclusionBaseline 18F-FDG PET/CT-derived metabolic parameters may serve as promising imaging biomarkers for predicting the prognosis of adults with multifocal LCH.
Indexed as
Identifiers
41619166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.